Prostate cancer screening 2026: what the new ACS PSA guidelines say for men
The American Cancer Society now recommends routine PSA blood tests for many men aged 50 to 69. Who should screen, how often, what counts as high, and what to ask.
revns editorial · Published November 12, 2026 · 7 min read
ACS 2026: PSA every 2 years for average-risk men 50–69; yearly from 45 for many Black men and some with family history; high PSA is 3 ng/mL under 70; USPSTF still individualized.
On 12 November 2026 the American Cancer Society (ACS) published a new guideline for prostate cancer early detection. For the first time since 2010 it recommends scheduled PSA blood tests for many asymptomatic men, not only optional tests after a one-to-one talk. Average-risk men aged 50 to 69 should have a PSA test every two years. Black men and many men with a close family history should start at age 45, often every year through 69. That is a practical change for millions of men who train, work and see a primary care doctor for blood work anyway.
TL;DR
| Who | ACS 2026 screening |
|---|---|
| Average risk, ages 50–69 | PSA every 2 years |
| Black men, ages 45–69 | PSA every year |
| Family history, ages 45–69 | Yearly if a father, brother or son had prostate cancer before 65, or more than one close relative; every 2 years if one relative was diagnosed at 65 or older |
| Ages 70–74 | Shared decision; every 2 years if you choose to continue |
| Ages 75+ | Not recommended (with narrow exceptions to discuss) |
| Poor health, under 10 years life expectancy | Not recommended at any age |
| PSA “high” | ≥ 3 ng/mL if under 70; ≥ 6.5 ng/mL if 70+; repeat in 2–12 weeks, then MRI and/or biomarkers before many biopsies |
Why did the American Cancer Society change its mind?
Between 2010 and 2026, ACS told average-risk men to choose screening after learning benefits and harms, mirroring an era when many groups worried that PSA tests led to overdiagnosis and overtreatment of slow-growing cancers. New evidence, including updated reviews of screening trials, shifted the balance for some age groups toward finding cancers earlier and lowering prostate-cancer deaths, especially when follow-up uses MRI and active surveillance instead of immediate surgery for low-risk disease.
The published guideline is American Cancer Society guideline for the early detection of prostate cancer, 2026 (Hoffman et al., CA: A Cancer Journal for Clinicians). ACS also published a plain-language patient summary the same day.
What exactly should men do under the new ACS schedule?
The consumer summary on cancer.org spells out age bands:
Average risk. Most men are not in a higher-risk category. From 50 through 69, get a PSA test every two years once you have heard the benefits, limits and possible harms, what happens if PSA is high, and that active surveillance is the usual first step for many low-risk cancers.
Higher risk — Black men. Begin at 45 with yearly PSA through 69. Black men in the United States face higher incidence and mortality from prostate cancer; the guideline authors cite earlier and more aggressive presentation as one reason for earlier surveillance.
Higher risk — family history. Non-Black men with prostate cancer in a father, brother or son also start at 45:
- Every year if a close relative was diagnosed before 65, or if more than one close relative had prostate cancer.
- Every 2 years if only one close relative was affected and diagnosis was at 65 or older.
Inherited risk. Men with known high-risk gene changes (for example BRCA2) or untested relatives with such mutations should agree start age and interval with their clinician.
Ages 70–74. Benefits and harms are less clear. Continue only if you and your clinician agree; if you screen, every two years.
75 and older. ACS does not recommend routine screening. Very healthy men 75–79 with a rising PSA trend may discuss continuing; screening is discouraged after 80 and when life expectancy is under 10 years.
ACS does not recommend the digital rectal exam (DRE) as a screening test, though it may still be used in work-up when PSA is abnormal.
What PSA level counts as abnormal?
Many US lab reports still flag PSA below 4.0 ng/mL as “normal.” The 2026 ACS threshold is lower for younger men:
- 3 ng/mL or higher if you are younger than 70
- 6.5 ng/mL or higher if you are 70 or older
If PSA is high, repeat the blood test in about two to twelve weeks. If it is still high, most men should have prostate MRI and/or a biomarker blood or urine test to refine biopsy decisions. Some men with very high PSA may go straight to biopsy; that is a clinical call.
A high PSA does not always mean cancer. Benign prostate enlargement, prostatitis and recent ejaculation or vigorous cycling can raise PSA. That is why confirmation and imaging matter.
How does this compare with the USPSTF?
The US Preventive Services Task Force has not yet published a new final recommendation. Its 2018 statement still says men 55 to 69 should decide individually with a clinician (grade C), and it recommends against screening men 70 and older (grade D). The USPSTF website lists prostate cancer screening as “update in progress.”
In practice you may hear different advice from ACS, your health system and insurers until USPSTF finishes its review. Bring a written summary of your risk (age, race/ethnicity, family history) and ask which guideline your clinician follows.
Outside the United States: the UK NHS does not run a national prostate screening programme like breast or bowel screening. Men can request a PSA test after an informed discussion with a GP. Canadian and Australian policies also differ. This article focuses on the ACS 2026 US guideline; adapt questions to your local system.
What is active surveillance, and why does it matter for active men?
If screening finds low-risk prostate cancer, ACS expects active surveillance as the first management option: regular PSA, repeat biopsies and sometimes MRI, with treatment only if the cancer shows signs of growth.
That matters for men who lift, run or cycle: immediate surgery or radiation can carry urinary, sexual and bowel side effects. Surveillance lets many men keep training while the tumour is watched. It is not “doing nothing”; it is structured follow-up.
Where do fitness, sleep and weight fit in?
Screening does not replace healthy habits. ACS’s separate diet and physical activity guideline for cancer prevention recommends staying active and eating a diet rich in vegetables, fruits and whole grains. For day-to-day training:
- Strength work two or more days a week supports muscle and bone as you age; see strength training for beginners if you are new.
- Sleep and protein underpin recovery; see how much sleep you need and how much protein per day.
- Cardiorespiratory fitness from Zone 2 training supports heart health, which remains a leading concern for men in mid-life.
revns does not store PSA results, order tests or interpret labs. It helps you log training, sleep, meals and recovery so you see patterns next to your weekly check-in habits. Use clinical portals for lab history.
What should you do this week?
- Check your age and risk band against the table above.
- If you are 45–69 and due for screening, book a clinician visit or ask at your next blood draw whether PSA is included. Many men already have venous blood taken annually; adding PSA may be a single line on the lab order.
- Write down family history: who had prostate cancer and at what age.
- Before the test, ask what PSA threshold your clinic uses for referral and what follow-up (repeat test, MRI) they prefer.
- Keep training and sleep consistent; avoid a hard new leg day or long bike session right before PSA if your clinician asks you to, since exertion can sometimes affect results.
When should you see a clinician urgently?
Ask for prompt assessment, with or without a recent PSA, if you have:
- New difficulty starting or stopping urine flow, weak stream, or inability to urinate
- Blood in urine or semen
- Bone pain, especially in the back or hips, with no injury
- Unexplained weight loss or persistent pelvic pain
Red flags during biopsy or treatment planning (fever after biopsy, heavy bleeding) need same-day or emergency care per local instructions.
revns is training guidance, not a medical record. It does not diagnose cancer or recommend treatment.
How often will guidelines change again?
Prostate screening guidance has shifted three times in fifteen years as trial follow-up lengthened and imaging improved. Expect USPSTF and insurance rules to update after their review. Save your PSA dates and values (from your patient portal) so you can see trends even when advice changes.
What questions should you ask at your appointment?
Useful prompts for a ten-minute visit:
- Am I average or higher risk for prostate cancer given my age, race and family history?
- Does this clinic follow ACS 2026, USPSTF 2018, or another policy for PSA intervals?
- What PSA number triggers a repeat test here, and how soon should I retest?
- If PSA stays high, do you order MRI before biopsy, and is active surveillance offered for low-risk results?
- Will my insurer cover PSA on this schedule while USPSTF review is pending?
Write the answers in your health app or a note on your phone. revns is for training logs, not clinical records, but keeping screening dates beside your sleep and load data helps you notice when life stress or travel might have affected a blood draw.
Related
- Strength training for beginners
- Zone 2 training explained
- How much sleep do you need?
- AI fitness coach and week planner
- BMI calculator
This is general training and health literacy guidance, not medical advice. Screening and treatment decisions belong with a qualified clinician who knows your history.
Sources
- Hoffman RM, Wolf AMD, Etzioni R, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA Cancer J Clin 2026
- American Cancer Society. Guideline for prostate cancer early detection (patient summary, revised 12 Nov 2026)
- US Preventive Services Task Force. Prostate cancer: screening (2018 recommendation; update in progress)
- Merelli A. American Cancer Society revises guidelines, urges routine PSA screening. STAT 12 Nov 2026
Terms in this post
revns publishes training and nutrition guidance, not medical advice. See a clinician for symptoms, injury or a medical condition. Accurate as of November 12, 2026.
